ワクチンアジュバントの世界市場:粒子状アジュバント、アジュバント・エマルション、病原体、サポニン、組合せアジュバント

◆英語タイトル:Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021
◆商品コード:BT-4378
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2016年6月15日
◆ページ数:158
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥644,100見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、ワクチンアジュバントの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品種類別分析、投与経路別分析、疾患種類別分析、用途別分析、市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.
The vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5%. This market is segmented based on product type, route of administration, disease type, applications, and application category.

On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.

Based on route of administration, the vaccine adjuvants market includes oral route, subcutaneous route, intranasal route, intramuscular route, intradermal route, and other routes. The intramuscular segment is expected to account for the largest share of the global market in 2016. Rising geriatric population and vaccines for improved immunization are the key factors propelling the growth of this market.

Based on disease type, the vaccine adjuvants market comprises of infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global market in 2016. High prevalence of infectious diseases and cancer is expected to drive market growth in the coming years.

Based on applications, the vaccine adjuvants market is segmented into research applications and commercial applications. The research applications segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to factors such as ongoing research on new adjuvants, increasing initiatives by government bodies and companies, usage of many vaccine adjuvants commercially, increasing incidences of zoonotic diseases, and increase in the number of conferences and summits.

Based on application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. The human vaccine adjuvants segment is expected to account for the largest share of the global market in 2016 and is expected to have a higher growth rate in the application category segment. The large share of this segment can be attributed to the increasing initiatives by companies, vaccine adjuvants discovery and development, and increase in the number of conferences and summits.

Based on geography, the global vaccine adjuvants market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China and India. Rising prevalence of infectious diseases, increasing government investments for vaccine research and development, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian region.

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MPV Technologies (U.S.), and OZ Biosciences (France).

【レポートの目次】

1 Introduction (Page No. – 14)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Segmentation
1.3.2 Markets Covered
1.3.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Key Indicators
2.1.1 Introduction
2.1.2 Macroindicators
2.1.2.1 Rapid Growth of Aging Population
2.1.2.2 Incidence and Prevalence of Cancer
2.1.2.3 Burden of Infectious Diseases
2.1.2.4 Healthcare Expenditure Patterns
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Key Data From Secondary Sources
2.5 Key Data From Primary Sources
2.6 Key Industry Insights
2.7 Assumptions for the Study

3 Executive Summary (Page No. – 32)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 38)
4.1 Market Overview
4.2 Market, By Application
4.3 Geographical Snapshot of the Market
4.4 Geographic Analysis: Market, By Application Category
4.5 Geographic Analysis: Market, By Disease Type
4.6 Lifecycle Analysis, By Region, 2015

5 Market Overview (Page No. – 44)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Use of Adjuvants in Vaccine
5.2.1.2 High Prevalence of Infectious and Zoonotic Diseases
5.2.1.3 Increase in Livestock and Instances of Diseases
5.2.1.4 Increasing Focus on Immunization Programs From Various Government Bodies
5.2.1.5 Technological Advancements in Aluminum Hydroxide-Based Adjuvants
5.2.1.6 Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
5.2.1.7 Increasing Geriatric Population
5.2.2 Restraints
5.2.2.1 High Cost of Adjuvant Research
5.2.2.2 Stringent Regulatory Environment and Time-Consuming Approvals
5.2.3 Opportunities
5.2.3.1 Combination Adjuvants
5.2.3.2 Pandemic Diseases
5.2.4 Challenges
5.2.4.1 Identification of Adjuvants
5.2.5 Trends
5.2.5.1 Collaborations
5.3 Key Pipeline Products
5.4 Regulatory Landscape
5.4.1 North America
5.4.2 Europe
5.4.2.1 Manufacturing Specifications
5.4.2.2 Routine Testing
5.4.2.3 Stability
5.4.3 Asia
5.4.4 RoW

6 Global Vaccine Adjuvants Market, By Product Type (Page No. – 58)
6.1 Introduction
6.2 Particulate Adjuvants
6.3 Adjuvant Emulsions
6.4 Pathogen Components
6.5 Combination Adjuvants
6.6 Others

7 Global Vaccine Adjuvants Market, By Route of Administration (Page No. – 72)
7.1 Introduction
7.2 Intramuscular Route
7.3 Subcutaneous Route
7.4 Intranasal Route
7.5 Oral Route
7.6 Intradermal Route
7.7 Others

8 Global Vaccine Adjuvant Market, By Disease Type (Page No. – 81)
8.1 Introduction
8.2 Infectious Diseases
8.3 Cancer
8.4 Others

9 Global Vaccine Adjuvants Market, By Application (Page No. – 88)
9.1 Introduction
9.2 Research Application
9.3 Commercial Application

10 Global Vaccine Adjuvants Market, By Application Category (Page No. – 93)
10.1 Introduction
10.2 Human Vaccine Adjuvants
10.3 Veterinary Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By Region (Page No. – 98)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Rest of Europe
11.4 Asia
11.4.1 China
11.4.2 India
11.4.3 Rest of Asia
11.5 Rest of the World

12 Competitive Landscape (Page No. – 125)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
12.3.1 Agreements & Collaborations
12.3.2 Acquisitions
12.3.3 Expansions
12.3.4 Others

13 Company Profile (Page No. – 130)
(Overview, Financial*, Products & Services, Strategy, and Developments)
13.1 Introduction
13.2 Brenntag Biosector A/S (A Subsidiary of Brenntag AG)
13.3 Seppic (A Subsidiary of Air Liquide Group)
13.4 CSL Limited
13.5 Agenus, Inc.
13.6 Novavax, Inc.
13.7 Invivogen
13.8 SPI Pharma, Inc. (A Subsidiary of Associated British Foods PLC.)
13.9 Avanti Polar Lipids, Inc.
13.10 MPV Technologies, Inc.
13.11 OZ Biosciences

*Details Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. – 148)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Available Customizations
14.5 Introducing RT: Real-Time Market Intelligence
14.6 Related Reports

List of Tables (90 Tables)

Table 1 Increasing Use of Adjuvants in Vaccine-Preventable Diseases Drives the Market Growth
Table 2 High Cost of Adjuvant Research Restraints the Market Growth
Table 3 Combined Adjuvants and Pandemic Diseases Offer Growth Opportunities for Market Players
Table 4 Identification of Adjuvants Challenges the Growth of This Market
Table 5 Collaborations Offer Growth Trends for Market Players
Table 6 Fda Approved Vaccine Adjuvants
Table 7 Licensed Vaccines Containing Adjuvants
Table 8 Examples of Vaccine Adjuvants in Clinical Trials
Table 9 Vaccine Adjuvants Market Size, By Product Type, 2014–2021
Table 10 List of Particulate Adjuvants Approved for Human Use (2015)
Table 11 Particulate Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 12 North America Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 13 Europe Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 14 Asia Particulate Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 15 List of Adjuvant Emulsions Approved for Human Use (2015)
Table 16 Adjuvants Emulsion Market Size, By Region, 2014–2021(USD Million)
Table 17 North America Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 18 Europe Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 19 Asia Adjuvant Emulsions Market Size, By Country, 2014–2021(USD Million)
Table 20 Pathogen Components and Its Description
Table 21 Pathogen Components Market Size, By Region, 2014–2021(USD Million)
Table 22 North America Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 23 Europe Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 24 Asia Pathogen Components Market Size, By Country, 2014–2021(USD Million)
Table 25 List of Combination Adjuvant Approved for Human Use (2015)
Table 26 Combination Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 27 North America Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 28 Europe Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 29 Asia Combination Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 30 Other Adjuvants and Its Description
Table 31 Others Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 32 North America Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 33 Europe Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 34 Asia Others Vaccine Adjuvants Market Size, By Country, 2014–2021(USD Million)
Table 35 Vaccine Adjuvants Market Size, By Route of Administration, 2014–2021(USD Million)
Table 36 Intramuscular Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 37 Subcutaneous Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 38 Intranasal Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 39 Oral Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 40 Intradermal Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 41 Others Route of Administration Market Size, By Region, 2014–2021(USD Million)
Table 42 Market Size, By Disease Type, 2014–2021(USD Million)
Table 43 New Cases of Diseases (2014)
Table 44 Infectious Diseases Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 45 Cancer Disease Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 46 Others Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 47 Vaccine Adjuvants Market Size, By Application, 2014–2021(USD Million)
Table 48 Vaccine Adjuvants Market, By Research Application, By Region, 2014–2021(USD Million)
Table 49 Vaccine Adjuvants Market, By Commercial Application, By Region, 2014–2021(USD Million)
Table 50 Market Size, By Application Category, 2014–2021 (USD Million)
Table 51 List of Adjuvants Approved for Human Use By Fda
Table 52 Human Vaccine Adjuvants Market Size, By Region, 2014–2021 (USD Million)
Table 53 Veterinary Vaccine Adjuvants Market Size, By Region, 2014–2021(USD Million)
Table 54 Market Size, By Region, 2014–2021 (USD Million)
Table 55 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 56 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 57 Asia: Market Size, By Country, 2014–2021 (USD Million)
Table 58 North America: Market Size, By Product Type, 2014–2021 (USD Million)
Table 59 North America: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 60 North America: Market Size, By Disease Type, 2014–2021(USD Million)
Table 61 North America: Market Size, By Application, 2014–2021(USD Million)
Table 62 North America: Market Size, By Application Category, 2014–2021(USD Million)
Table 63 U.S.: Market Size, By Product Type, 2014–2021, (USD Million)
Table 64 Canada: Market Size, By Product Type, 2014–2021(USD Million)
Table 65 Europe: Market Size, By Product Type, 2014–2021 (USD Million)
Table 66 Europe: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 67 Europe: Market Size, By Disease Type, 2014–2021(USD Million)
Table 68 Europe: Market Size, By Application, 2014–2021(USD Million)
Table 69 Europe: Market Size, By Application Category, 2014–2021 (USD Million)
Table 70 Germany: Market Size, By Product Type, 2014–2021 (USD Million)
Table 71 U.K.: Market Size, By Product Type, 2014–2021 (USD Million)
Table 72 France: Market Size, By Product Type, 2014–2021 (USD Million)
Table 73 Rest of Europe: Market Size, By Product Type, 2014–2021 (USD Million)
Table 74 Asia: Market Size, By Product Type, 2014–2021 (USD Million)
Table 75 Asia: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 76 Asia: Market Size, By Disease Type, 2014–2021(USD Million)
Table 77 Asia: Market Size, By Application, 2014–2021(USD Million)
Table 78 Asia: Market Size, By Application Category, 2014–2021(USD Million)
Table 79 China: Market Size, By Product Type, 2014–2021 (USD Million)
Table 80 India: Market Size, By Product Type, 2014–2021 (USD Million)
Table 81 Rest of Asia:Market Size, By Product Type, 2014–2021 (USD Million)
Table 82 Rest of the World: Market Size, By Product Type, 2014–2021 (USD Million)
Table 83 Rest of the World: Market Size, By Route of Administration, 2014–2021 (USD Million)
Table 84 Rest of the World: Market Size, By Disease Type, 2014–2021(USD Million)
Table 85 Rest of the World: Market Size, By Application, 2014–2021(USD Million)
Table 86 Rest of the World: Market Size, By Application Category, 2014–2021(USD Million)
Table 87 Agreements & Collaborations, 2015
Table 88 Acquisitions, 2015–2016
Table 89 Expansions, 2014
Table 90 Others, 2014–2015

List of Figures (42 Figures)

Figure 1 Research Design
Figure 2 Increase in Aging Population, By Country (2010 vs 2015)
Figure 3 Percentage Increase in Aging Population, By Region (1980–2010 vs 2010–2040)
Figure 4 Global Burden of Cancer, By Region (2005–2030)
Figure 5 Number of New Cancer Cases By Country
Figure 6 Healthcare Expenditure Across Major Countries, 2000 vs 2012
Figure 7 Healthcare Spending Matrix, By Country (2013)
Figure 8 Market Size Estimation: Top-Down Approach
Figure 9 Market Size Estimation: Bottom-Up Approach
Figure 10 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 11 Data Triangulation Methodology
Figure 12 Vaccine Adjuvants Market Size, By Product Type, 2016 vs 2021 (USD Million)
Figure 13 Global Vaccine Adjuvants Market Size, By Route of Administration, 2016 vs 2021 (USD Million)
Figure 14 Global Vaccine Adjuvants Market Size, By Disease Type, 2016 vs 2021 (USD Million)
Figure 15 Global Vaccine Adjuvants Market Size, By Application, 2016 vs 2021 (USD Million)
Figure 16 Global Vaccine Adjuvants Market Size, By Application Category, 2016 vs 2021 (USD Million)
Figure 17 Global Vaccine Adjuvants Market, By Region, 2016 (USD Million)
Figure 18 The Vaccine Adjuvants Market is Expected to Showcase High Growth Opportunities During the Forecast Period
Figure 19 The Research Application Segment is Expected to Account for the Largest Market Share in 2016
Figure 20 Asian Countries are Expected to Witness the Highest Growth Rate During the Forecast Period
Figure 21 The Human Vaccine Adjuvants Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 22 The Infectious Disease Segment Will Continue to Dominate the Market in 2021
Figure 23 Asia is Expected to Witness the Highest Growth Rate in the Vaccine Adjuvants Market During the Forecast Period
Figure 24 The Particulate Adjuvants Segment is the Largest Segment of the Vaccine Adjuvants Market From 2016 to 2021
Figure 25 The Intranasal Route of Administration Segment is Expected to Grow at the Highest CAGR During the Forecast Period From 2016 to 2021
Figure 26 The Cancer Disease Type Segment is Projected to Grow at the Highest CAGR During the Forecast Period
Figure 27 Cancer Incidence, By Region, 2012–2020
Figure 28 The Research Application Segment is the Largest in the Vaccine Adjuvants Market From 2016 to 2021
Figure 29 Human Vaccine Adjuvants Accounts for the Largest Share in Vaccine Adjuvant Market, By Application Category, in 2016
Figure 30 Asia is Expected to Witness the Highest Growth in the Vaccine Adjuvants Market During the Forecast Period
Figure 31 North America: Vaccine Adjuvants Market Snapshot
Figure 32 European Vaccine Adjuvants Market Snapshot
Figure 33 Asia: Vaccine Adjuvants Market Snapshot
Figure 34 Agreements & Collaborations Was the Key Growth Strategy for Market Players, 2013–2016
Figure 35 Global Vaccine Adjuvants Market Share Analysis, By Key Players, 2015
Figure 36 Battle for Market Share: Agreements & Collaborations Was the Key Strategy Adopted By Market Players
Figure 37 Product Benchmarking for Major Players
Figure 38 Company Snapshot: Brenntag AG
Figure 39 Company Snapshot: Air Liquide Group
Figure 40 Company Snapshot: CSL Limited
Figure 41 Company Snapshot: Agenus, Inc.
Figure 42 Company Snapshot: Novavax, Inc.

【レポートのキーワード】

ワクチン・アジュバント、粒子状アジュバント、アジュバントエマルション、病原体、サポニン、組合せアジュバント、投与経路、疾患、感染症、がん、アジュバント用途、医薬品

★調査レポート[ワクチンアジュバントの世界市場:粒子状アジュバント、アジュバント・エマルション、病原体、サポニン、組合せアジュバント]販売に関する免責事項
★調査レポート[ワクチンアジュバントの世界市場:粒子状アジュバント、アジュバント・エマルション、病原体、サポニン、組合せアジュバント]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆